Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole blood transfusion Clear all
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Laser Photocoagulation in Twin to Twin Transfusion Syndrome

NCT02506049
View directory record Official record
Conditions
Twin to Twin Transfusion Syndrome
Interventions
S-LPC:Selective Laser Photocoagulation
Device
Lead sponsor
University of Tennessee
Other
Eligibility
16 Weeks to 27 Weeks · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 14, 2026, 8:19 AM EDT
Suspended Not applicable Interventional

Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome

NCT04137692
View directory record Official record
Conditions
Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1
Interventions
Red Blood Cell Transfusion
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
16 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Not applicable Interventional

Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2

NCT03019367
View directory record Official record
Conditions
Intraventricular Haemorrhage Neonatal, Death; Neonatal
Interventions
Umbilical cord milking UCM, Delayed cord clamping DCC
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 33 Weeks
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adverse Effects of RBC Transfusions: A Unifying Hypothesis

NCT00838331
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fresh blood, Aged blood
Biological
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 14, 2026, 8:19 AM EDT
Not yet recruiting Phase 2 Interventional

Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis

NCT07674745
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin, Treatment as Usual
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Improving White Blood Cell Collection From Healthy Donors

NCT01553214
View directory record Official record
Conditions
Allogeneic Granulocyte Donation
Interventions
Filgrastim, Dexamethasone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 14, 2026, 8:19 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

NCT03715972
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions
Hydroxyurea, Acetazolamide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
7 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 2 Interventional Results available

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

NCT03182751
View directory record Official record
Conditions
Hip Fractures, Intertrochanteric Fractures
Interventions
Tranexamic Acid (TXA), Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 14, 2026, 8:19 AM EDT
Terminated Not applicable Interventional

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 14, 2026, 8:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

NCT03653338
View directory record Official record
Conditions
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa
Biological · Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
5 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Completed No phase listed Observational

Evaluating URMC's Massive Transfusion Protocol

NCT02083549
View directory record Official record
Conditions
Blood Coagulation Disorders, Trauma, Acute Coagulopathy
Interventions
Blood collection
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Phase 1 Interventional

Red Cell Transfusion Goals in Patients With Acute Leukemias

NCT02086773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Withdrawn No phase listed Observational

The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates

NCT01914211
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Tranexamic Acid, Acute Normovolemic Hemodilution
Drug · Procedure
Lead sponsor
Aymen N Naguib
Other
Eligibility
Up to 28 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 14, 2026, 8:19 AM EDT
Completed No phase listed Observational Results available

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

NCT05340751
View directory record Official record
Conditions
Anesthesia
Interventions
Blood drawn
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
40 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
View directory record Official record
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 14, 2026, 8:19 AM EDT
Active, not recruiting Phase 3 Interventional

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin Alfa
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
33
States / cities
Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 14, 2026, 8:19 AM EDT
Terminated Phase 3 Interventional

ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

NCT00654433
View directory record Official record
Conditions
Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases, Inborn Errors of Metabolism, Mucopolysaccharidosis
Interventions
ALD-101
Biological
Lead sponsor
Aldagen
Industry
Eligibility
Up to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 14, 2026, 8:19 AM EDT
Withdrawn Phase 2 Interventional

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

NCT02047552
View directory record Official record
Conditions
Functional Iron Deficiency, Trauma, Anemia
Interventions
Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 14, 2026, 8:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

NCT02684747
View directory record Official record
Conditions
Blood Transfusion, Autologous, Blood Doping
Interventions
Autologous Transfusion, Control - Normal Saline (Placebo)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 14, 2026, 8:19 AM EDT
Recruiting Phase 3 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Elritercept, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
25
States / cities
Duarte, California • Glendale, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 8:19 AM EDT